Founded in 1996 by Walter Gilbert, Ph.D. and Stuart B. Levy, M.D., Paratek Pharmaceuticals is focused on the discovery, development, and commercialization of medicines designed to save lives and alleviate suffering.

Our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern.

Latest News

PRTK November 2015 Presentation (pdf)

Special Cash Dividend

On October 14, 2014 Transcept Pharmaceuticals declared a special cash dividend, in connection with its merger with Paratek Pharmaceuticals.